Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and D-amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three substances induce distinct acute subjective effects. However, differences in acute responses to these prototypical psychoactive substances have not been characterized in a controlled study. We investigated the acute autonomic, subjective, and endocrine effects of single doses of LSD (0.1 mg), MDMA (125 mg), D-amphetamine (40 mg), and placebo in a randomized, double-blind, cross-over study in 28 healthy subjects. All of the substances produced comparable increases in hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses at the doses used. LSD and MDMA increased heart rate more than D-amphetamine, and D-amphetamine increased blood pressure more than LSD and MDMA. LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine. LSD also produced greater subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine. LSD also induced greater impairments in subjective ratings of concentration, sense of time, and speed of thinking compared with MDMA and D-amphetamine. MDMA produced greater ratings of good drug effects, liking, high, and ego dissolution compared with D-amphetamine. D-Amphetamine increased ratings of activity and concentration compared with LSD. MDMA but not LSD or D-amphetamine increased plasma concentrations of oxytocin. None of the substances altered plasma concentrations of brain-derived neurotrophic factor. These results indicate clearly distinct acute effects of LSD, MDMA, and D-amphetamine and may assist the dose-finding in substance-assisted psychotherapy research.
useful to assist psychotherapy. Whether and how the effects of MDMA are similar or differ from the classic stimulant \(\alpha\)-amphetamine and classic hallucinogen LSD have not been studied under double-blind conditions in the same study. Comparative studies, particularly within-subjects comparisons of the acute effects of these prototypical substances, are lacking. Therefore, we compared for the first time the acute subjective, autonomic, and endocrine effects of doses with similar cardiovascular activity ("equivalent" doses) of LSD (0.1 mg), MDMA (125 mg), \(\alpha\)-amphetamine (40 mg), and placebo in a cross-over study in healthy subjects. By comparing all three substances using a within-subject design, it is possible to directly assess differences and commonalities of these substances. Moreover, by including different substances with partially overlapping effects, it is also possible to considerably improve blinding. This latter point has been a serious shortcoming of almost all previous studies, which compared effects of MDMA and LSD, respectively, with non-active placebo, which almost inevitably results in unblinding. Dose selection was critical because we could only compare single doses of each substance in this within-subjects study. LSD was used at an intermediate dose of 0.1 mg that is representative of doses that are used recreationally [36] and in research [2]. A higher dose of 0.2 mg LSD has previously been shown to produce greater subjective effects than the 0.1 mg dose [37, 38], but was not used in the present study because it was expected to produce greater alterations of waking consciousness than any of the other substances and would not have allowed brain imaging due to expected anxiety and movement artifacts in the scanner. MDMA was used at a high dose (125 mg) that produces the full range of empathogenic MDMA-typical effects [27] and is considered safe [39], and at the upper range of doses used in research investigating the safety and efficacy of MDMA-assisted psychotherapy in the treatment of PTSD [12] and in experimental studies in healthy participants [27, 39, 40]. Preferred recreational doses are slightly lower and in the range of 80–120 mg [41]. Higher doses are expected to produce larger subjective positive responses, but considerably more adverse effects [39, 41]. \(\alpha\)-Amphetamine was also used at a rather high dose (40 mg) that is in the upper range of doses that are used in patients and in research [31, 32, 34, 42–44].

The main goal of the present study was to describe and compare the subjective and autonomic effects of all three substances over time and determine plasma concentration–time profiles (pharmacokinetics). We hypothesized that LSD would induce more pronounced and different alterations of waking consciousness, assessed by the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale and Mystical Experience Questionnaire (MEQ) compared with MDMA and \(\alpha\)-amphetamine [37]. We predicted that MDMA would produce distinct subjective emotional effects compared with \(\alpha\)-amphetamine [25, 27, 28] and induce greater increases in plasma concentrations of oxytocin than LSD and \(\alpha\)-amphetamine [3, 14]. Finally, we explored effects on plasma concentrations of brain-derived neurotrophic factor (BDNF), a biomarker that is linked to neurogenesis, because psychedelics have been shown to have neuroregenerative potential and may alter BDNF [45, 46]. Altogether, we tested whether prototypical hallucinogens, empathogens, and psychotomimetics are indeed substances with distinct acute-effect profiles in humans for the first time using a head-to-head comparison with the same study and participants.

MATERIALS AND METHODS
Study design
We used a double-blind, placebo-controlled, cross-over design with four experimental test sessions to investigate the responses to 0.1 mg LSD, 125 mg MDMA, 40 mg \(\alpha\)-amphetamine, and placebo in 28 healthy participants (14 females, 14 males). The washout period between sessions was at least 10 days. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee northwest Switzerland (EKNZ). The administration of LSD, MDMA, and \(\alpha\)-amphetamine in healthy subjects was authorized by the Swiss Federal Office for Public Health, Bern, Switzerland. All of the participants provided written consent before participating in the study, and they were paid for their participation. The study was registered at ClinicalTrials.gov (NCT03019822).

Participants
Twenty-eight healthy subjects (14 men, 14 women; 28 ± 4 years old [mean ± SD]; range, 25–45 years; body weight, 71.5 ± 12.0 kg) were recruited from the University of Basel. Participants who were younger than 25 years old were excluded from participating in the study because of the higher incidence of psychotic disorders and because low age has been associated with more anxious reactions to hallucinogens [47]. Additional exclusion criteria were age >50 years, pregnancy (urine pregnancy test at screening and before each test session), personal or family (first-degree relative) history of major psychiatric disorders (assessed by the Semi-structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Axis I disorders by a trained psychiatrist), the use of medications that may interfere with the study medications (e.g. antidepressants, antipsychotics, sedatives), chronic or acute physical illness (abnormal physical exam, electrocardiogram, or hematological and chemical blood analyses), tobacco smoking (>10 cigarettes/day), lifetime prevalence of illicit drug use >10 times (except for \(\Delta^9\)-tetrahydrocannabinol), illicit drug use within the last 2 months, and illicit drug use during the study (determined by urine drug tests). A previous study found no difference in the response to LSD between hallucinogen-naive and moderately experienced subjects (<10 times) [3]. However, we wanted to exclude frequent substance users because extensive previous uncontrolled experiences may influence condition new substance experiences [47]. The participants were asked to abstain from excessive alcohol consumption between test sessions (no more than 10 standard drinks/week) and particularly limit their use to one drink on the day before the test sessions. Additionally, the participants were not allowed to drink xanthine-containing liquids after midnight before the study day.

Five participants had previously used a hallucinogen, including LSD (three participants, 1–4 times), DMT (one participant 4 times), and salvia divinorum (one participant 3 times); eight participants had used MDMA (1–5 times), and 13 participants had previously used a stimulant, including methylphenidate (six participants, 1–3 times), amphetamine (eight participants, 1–2 times), and cocaine (one participant, 4 times). Eight participants had never used any illicit drugs with the exception of cannabis.

We performed urine drug tests at screening and before each test session, and no substances were detected during the study. We did not screen for alcohol use.

Study procedures
The study included a screening visit, a psychiatric interview, four 12-h experimental sessions, and an end-of-study visit. The experimental sessions were conducted in a quiet standard hospital patient room. Only one research subject and one investigator were present during the experimental sessions. The participants could interact with the investigator, rest quietly, or listen to music via headphones, but no other entertainment was provided. LSD, \(\alpha\)-amphetamine, or placebo was administered at 9:00 a.m. MDMA or placebo was administered at 9:30 a.m. This was because of the different times to peak effects for each substance so that the functional magnetic resonance imaging (fMRI) scan and other assessments could be performed during the expected time-matched peak drug effects [26, 27, 32, 48, 49]. The fMRI scan
was performed at 11:00 a.m.–12:00 p.m. and the fMRI findings will be published elsewhere. Autonomic and subjective effects were assessed repeatedly throughout the session. Blood was collected to determine endocrine effects and substance concentrations.

Study drugs
LSD (D-lysergic acid diethylamide base, high-performance liquid chromatography purity >99%; Lipomed AG, Arlesheim, Switzerland) was administered in a single intermediate oral dose of 100 µg [50]. D-Amphetamine sulfate (40 mg salt; Hänseler, Herisau, Switzerland) was administered in a relatively high dose in the form of gelatin capsules as a single oral dose that corresponded to 30 mg d-amphetamine base [32]. MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was prepared as gelatin capsules and administered as a single oral dose of 125 mg, which is considered a relatively high dose [28, 40, 51]. Blinding to treatment was guaranteed by using a double-dummy method, with identical capsules and vials that were filled with mannitol and ethanol, respectively, as placebo. At the end of each session and at the end of the study, the participants were asked to retrospectively guess their treatment assignment.

Measures
**Subjective effects.** Subjective effects were assessed repeatedly using visual analog scales (VASs) [14]. The VASs were presented as 100-mm horizontal lines (0–100%), marked from “not at all” on the left to “extremely” on the right (“slowed” and “racing” for “speed of thinking”). The VASs for “open,” “talkative,” “concentration,” “sense of time,” and “speed of thinking” [14]. The VASs were presented as 100-mm horizontal lines (0–100%), marked from “not at all” on the left to “extremely” on the right (“slowed” and “racing” for “speed of thinking”). The VASs were bidirectional (±50%), marked from “not at all” on the left (−50) to “normal” in the middle (0) and to “extremely” on the right (+50). The 60-item Adjective Mood Rating Scale (AMRS) was administered 1 h before and 1.5, 4, and 11 h after drug administration. The 5D-ASC scale was administered 1 h before and 1.5, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, and 11 h after drug administration (time specifications correspond to MDMA administration). The VASs included “any drug effect,” “good drug effect,” “bad drug effect,” “drug liking,” “drug high,” “stimulated,” “ego dissolution,” “talkative,” “concentration,” “sense of time,” and “speed of thinking” [54, 55]. The 60-item Adjective Mood Rating Scale (AMRS) was administered 1 h before and 1.5, 4, and 11 h after drug administration. The 5D-ASC scale was administered 1 h before and 1.5, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, and 11 h after drug administration.

**Statistical analyses.** For measures repeatedly taken over time during each session, we first determined the peak effects (E_max and/or E_min) and peak changes from baseline (Table 1). The values were then analyzed using repeated-measures analysis of variance, with drug as the sole within-subjects factor, followed by Tukey’s post hoc comparisons based on significant main effects. The criterion for significance was p < 0.05.

**RESULTS**
All 28 participants completed the MDMA, d-amphetamine, and placebo session. One participant quit before the final LSD session and only the data from the other sessions were included in the analysis.

**Subjective mood effects**
Subjective effects were measured over time using VASs (Fig. 1). The corresponding peak responses are presented in Table 1. LSD produced an overall greater response than both MDMA and d-amphetamine, reflected by significantly higher increases in ratings of “any drug effect,” “good drug effect,” “bad drug effect,” and “ego dissolution” compared with MDMA and d-amphetamine. LSD also produced greater “drug liking,” “drug high,” and “stimulation” than d-amphetamine, whereas the effects of LSD on these scales did not significantly differ from MDMA. MDMA and d-amphetamine but not LSD increased peak ratings of “concentration” compared with placebo and LSD (Table 1). In contrast, LSD induced greater mean reductions over time (Fig. 1) and greater maximal reductions of ratings of talkative, concentration, sense of time, and speed of thinking compared with MDMA and d-amphetamine (Table 1). Only LSD and not MDMA or d-amphetamine induced significant “bad drug effects” compared with placebo. The overall effects (“any drug effect”) of LSD, MDMA, and d-amphetamine lasted (mean ± SD) 8.5 ± 2.0 h, 4.4 ± 1.7 h, and 6.2 ± 2.0 h, respectively.

All three drugs similarly increased ratings of feeling “talkative” and “open.” MDMA produced higher ratings of “any drug effect,” “good drug effect,” “drug liking,” and “drug high” compared with d-amphetamine.

On the AMRS (Fig. 2, Table 1), LSD produced greater “introduction,” “inactivity,” “emotional excitation,” and “anxiety” compared with MDMA and d-amphetamine. Conversely, MDMA and d-amphetamine increased “extraversion” compared with LSD. D-Amphetamine also increased “activity” and “concentration” compared with LSD.

Oxytocin concentrations were measured using the oxytocin enzyme-linked immunosorbent assay (ELISA) kit (ENZO Life Sciences, Ann Arbor, MI) according to the manufacturer’s protocol as previously described [63]. The plasma levels of BDNF were measured at baseline and 3 and 5 h after drug administration. Plasma BDNF levels were measured using an ELISA kit (Biosensis Mature BDNF Rapid ELISA kit: human, mouse, rat; Thebarton, Australia) as previously described [64]. Analyses were performed at the end of the study in one batch.

**Plasma drug concentrations**
The plasma levels of LSD, d-amphetamine, and the LSD metabolite O-H-LSD were measured at baseline and 1, 1.5, 2, 3, 3.5, 4.5, 5, 6.5, 7.5, 9.5, and 11.5 h after drug administration. The plasma levels of MDMA and MDMA metabolites 3,4-methylenedioxyamphetamine (MDA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) were measured at baseline and 0, 0.5, 1, 1.5, 2.5, 3, 4, 5, 6, 7, 9, and 11 h after drug administration using liquid chromatography-tandem mass spectrometry as previously described [28, 32, 50]. The data were analyzed using non-compartmental analysis.

**Autonomic effects and adverse effects.** Blood pressure, heart rate, and tympanic body temperature were repeatedly measured 1 and 0.5 h before and 0.5, 1, 1.5, 2.5, 3, 3.4, 4, 5, 6, 7, 8, 9, 10, and 11 h after drug administration (time specifications correspond to MDMA administration) as previously described in detail [60]. Pupil function was measured under standardized dark-light conditions and assessed using a Voltcraft MS-1300 luxmeter (Voltcraft, Hirschau, Germany) after a dark adaption time of 1 min as previously described [61]. Adverse effects were assessed 1 h before and 11 h after drug administration using the 66-item List of Complaints [62]. This scale yields a total adverse effects score and reliably measures physical and general discomfort.

**Endocrine effects.** Plasma levels of oxytocin were measured at baseline and 1.5, 2.5, 3, and 5 h after MDMA administration.
Distinct acute effects of LSD, MDMA, and d-amphetamine
F Holze et al.

Table 1. Comparison of the acute effects of LSD, MDMA, d-amphetamine, and placebo

| Subjective effects | Placebo (mean ± SEM) | LSD (mean ± SEM) | MDMA (mean ± SEM) | d-Amphetamine (mean ± SEM) | F_{3,78} | P |
|--------------------|----------------------|------------------|-------------------|---------------------------|---------|---|
| VAS (%max)         |                      |                  |                   |                           |         |   |
| Any drug effect    | ΔE_{max} 1.6 ± 1.0   | 87 ± 3.3***      | 59 ± 5.8***       | 37 ± 4.8***               | 114.94  | <0.001 |
| Good drug effect   | ΔE_{max} 3.0 ± 2.5   | 82 ± 3.6***      | 64 ± 5.9***       | 45 ± 4.6***               | 89.09   | <0.001 |
| Bad drug effect    | ΔE_{max} 0.1 ± 0.1   | 31 ± 5.3***      | 8.7 ± 3.1***      | 4.9 ± 1.9***              | 18.26   | <0.001 |
| Drug liking        | ΔE_{max} 2.8 ± 2.4   | 76 ± 4.4***      | 64 ± 6.1***       | 48 ± 5.0***               | 63.95   | <0.001 |
| Drug high          | ΔE_{max} 3.7 ± 2.8   | 70 ± 5.9***      | 58 ± 6.5***       | 41 ± 6.0***               | 40.81   | <0.001 |
| Stimulated         | ΔE_{max} 3.4 ± 2.6   | 69 ± 6.1***      | 56 ± 6.6***       | 46 ± 6.0***               | 40.77   | <0.001 |
| Ego dissolution    | ΔE_{max} 0.9 ± 0.7   | 83 ± 10.2***     | 44 ± 7.9***       | 50 ± 13.0***              | 60.95   | <0.001 |
| Open               | ΔE_{max} 1.5 ± 1.0   | 21 ± 3.7***      | 24 ± 3.4***       | 22 ± 3.3***               | 13.02   | <0.001 |
| Talkative          | ΔE_{max} 1.2 ± 1.0   | 17 ± 3.2***      | 20 ± 3.5***       | 24 ± 3.0***               | 16.32   | <0.001 |
| Concentration      | ΔE_{min} −0.5 ± 0.5  | −31 ± 3.5***     | −12 ± 3.1***      | −47 ± 2.0***              | 32.05   | <0.001 |
| Sense of time      | ΔE_{max} 0.0 ± 0.0   | 6.6 ± 2.4        | 11 ± 3.0***       | 15 ± 2.8***               | 7.90    | <0.001 |
| Speed of thinking  | ΔE_{min} −0.8 ± 0.6  | −38 ± 2.6***     | −20 ± 3.3***      | −53 ± 1.3***              | 65.97   | <0.001 |
| AMRS score         | Activity 0.3 ± 0.3   | −0.1 ± 0.3       | 0.9 ± 0.4         | 2.2 ± 0.5***              | 6.74    | <0.001 |
|                   | Concentration 0.0 ± 0.0 | −0.7 ± 0.7     | 0.2 ± 0.4         | 1.5 ± 0.4***              | 4.05    | <0.01  |
|                   | Extroversion 0.2 ± 0.3 | −0.1 ± 0.5      | 2.4 ± 0.4***      | 2.7 ± 0.5***              | 11.70   | <0.001 |
|                   | Introversion 0.1 ± 0.1 | 5.7 ± 0.6***     | 2.1 ± 0.4***      | 0.8 ± 0.2***              | 45.37   | <0.001 |
|                   | Inactivity 0.4 ± 0.2   | 4.1 ± 0.6***     | 1.8 ± 0.4***      | 0.7 ± 0.2***              | 19.47   | <0.001 |
|                   | Well-being 0.4 ± 0.4   | 2.9 ± 1.1        | 4.7 ± 0.7***      | 4.8 ± 0.8***              | 7.49    | <0.001 |
|                   | Emotional excitation 0.5 ± 0.3 | 4.8 ± 1.2*** | 1.9 ± 0.5***     | 1.9 ± 0.6***              | 11.66   | <0.001 |
|                   | Anxiety 0.0 ± 0.0      | −33 ± 2.9***     | −15 ± 3.2***      | −23 ± 0.7***              | 47.91   | <0.001 |
| Autonomic effects  | Systolic blood pressure (mmHg) | E_{max} 129 ± 2.1 | 140 ± 2.6*** | 149 ± 2.8*** | 161 ± 2.9*** | 70.33 <0.001 |
|                   | Diastolic blood pressure (mmHg) | E_{min} 79 ± 13 | 88 ± 1.4*** | 89 ± 1.4*** | 97 ± 1.7*** | 61.42 <0.001 |
|                   | Heart rate (beats/min) | E_{max} 77 ± 2.0 | 92 ± 3.0*** | 88 ± 2.3*** | 87 ± 3.0*** | 20.20 <0.001 |
|                   | Rate–pressure product (beats·mmHg/min) | E_{max} 9639 ± 329 12725 ± 578*** 12707 ± 440*** 12042 ± 484*** 32.14 <0.001 |
|                   | Body temperature (°C) | E_{min} 37.2 ± 0.1 | 37.6 ± 0.1*** | 37.5 ± 0.0*** | 37.6 ± 0.0*** | 22.26 <0.001 |
|                   | Pupil size (mm) | E_{max} 6.3 ± 0.1 | 7.0 ± 0.1*** | 7.1 ± 0.1*** | 7.1 ± 0.1*** | 59.23 <0.001 |
|                   | Pupil size after light stimulus (mm) | E_{max} 4.4 ± 0.1 | 5.4 ± 0.1*** | 6.3 ± 0.2*** | 5.4 ± 0.1*** | 110.51 <0.001 |
|                   | Constriction amplitude (mm) | E_{min} 1.7 ± 0.1 | 1.4 ± 0.1* | 0.8 ± 0.1*** | 1.61 ± 0.04*** | 49.36 <0.001 |
| LC score           | Acute adverse effects 0–11 h | 2.9 ± 1.3 | 8.15 ± 2.02* | 5.43 ± 1.0 | 5.64 ± 1.37 | 2.63 NS |
|                   | Hormones | BDNF (mU/L) | E_{max} 2974 ± 425 | 2524 ± 370 | 3001 ± 423 | 2153 ± 265 | 1.27 NS |
|                   | Oxytocin (pg/mL) | E_{max} 259 ± 62 | 279 ± 60 | 809 ± 64*** | 194 ± 35*** | 27.36 <0.001 |

VAS visual analogue scale, AMRS Adjective Mood Rating Scale, LS List of Complaints, NS not significant, E_{max} maximal effect, ΔE_{max} maximal difference from baseline

*P < 0.05, **P < 0.01, ***P < 0.001 compared with placebo; *P < 0.05, **P < 0.01, ***P < 0.001 compared with LSD; †P < 0.05, ††P < 0.01, †††P < 0.001 compared with MDMA
LSD was the only drug that induced marked alterations of mind, reflected by large increases on all subscales of the SD-ASC (Fig. 3a, Supplementary Table S1) compared with placebo, MDMA (Tukey's post hoc tests: \( p < 0.001 \) for all comparisons), and \( \alpha \)-amphetamine \( (p < 0.001 \) for all comparisons). MDMA only significantly increased ratings of "blissful state" compared with placebo, whereas \( \alpha \)-amphetamine had no significant effects on any of the SD-ASC subscales.

LSD increased ratings on all scales of the MEQ43 and MEQ30 compared with MDMA, \( \alpha \)-amphetamine, and placebo \( (p < 0.001 \) for all comparisons), with the exception of nonsignificant differences in ratings of "deeply felt positive mood" for LSD and MDMA on the MEQ43 (Fig. 3b, Supplementary Table S1). MDMA significantly increased ratings of positive mood and ineffability (difficulty describing the experience in words) on the MEQ43 and MEQ30 compared with placebo \( (p < 0.01) \). \( \alpha \)-Amphetamine moderately increased positive mood ratings on the MEQ43 and MEQ30.

On the ARCI, LSD increased ratings on all subscales that indicated broad (mixed) hallucinogenic, sedative, and euphoriant effects (Supplementary Fig. S1), with the exception of a decrease on the benzodrine group scale, indicating lower stimulation. In contrast, \( \alpha \)-amphetamine was the only drug that increased ratings on the benzodrine group scale.

Vital signs and adverse effects
The effects of the drugs on vital signs over time are shown in Fig. 4, and peak effects are shown in Table 1. All active substances significantly increased blood pressure, heart rate, and body temperature compared with placebo. Systolic hypertension \( > 140 \) mmHg was seen in 23, 18, 14, and 3 participants after \( \alpha \)-amphetamine, MDMA, LSD, and placebo, respectively. Tachykyardia \( > 100 \) beats/min was seen in 5, 5, 7, and 0 participants after \( \alpha \)-amphetamine, MDMA, LSD, and placebo, respectively. \( \alpha \)-Amphetamine produced a significantly higher increase in blood pressure compared with LSD and MDMA, and LSD and MDMA produced lower heart rate increases than \( \alpha \)-amphetamine over the first 4 h, but all three drugs produced overall similar hemodynamic stimulation, considering the similar increases in the rate–pressure product. All three substances increased pupil size (Fig. 4, Table 1). However, only MDMA markedly and significantly impaired normal light-induced pupil constriction compared with placebo (Table 1, Supplementary Fig. S2). Only LSD increased the total acute \( (0–11 \) h) adverse effects score on the List of Complaints compared with placebo. Frequently reported adverse effects are presented in Supplementary Table S2. No severe adverse events were observed.

Endocrine effects
MDMA but not LSD or \( \alpha \)-amphetamine increased plasma concentrations of oxytocin (Fig. S4, Table 1). None of the substances altered plasma concentrations of BDNF (Fig. S4, Table 1).

Plasma drug concentrations
The concentration–time curves for LSD, O-H-LSD, \( \alpha \)-amphetamine, MDMA, MDA, and HMMA are shown in Supplementary Fig. S3. The geometric mean maximum \( (C_{\text{max}}) \) values (range) for LSD and O-H-LSD were 1.8 (0.99–2.9) and 0.12 (0.07–0.2) ng/ml, respectively. The \( T_{\text{max}} \) values were 1.6 (1.3–3.5) and 5.2 (3.1–7.5) h, respectively. The \( C_{\text{max}} \) values for MDMA, MDA, and HMMA were 236 (158–357), 10.9 (5.3–19), and 160 (43–287) ng/ml, respectively. The corresponding \( T_{\text{max}} \) values were 3.0 (1.1–5.0), 7.0 (3.0–11), and 2.8 (1.3–6.0) h, respectively. The \( C_{\text{max}} \) and \( T_{\text{max}} \) values for \( \alpha \)-amphetamine were 100 (68–133) ng/ml and 2.6 (1.0–5.5) h, respectively.
Blinding
Data on the participants’ retrospective identification of the study substances are shown in Supplementary Table S3. All of the participants correctly identified placebo, 96% correctly identified LSD, 75% correctly identified MDMA, and 75% correctly identified D-amphetamine. MDMA was misclassified as D-amphetamine and vice versa (21%). One participant (4%) misidentified LSD as MDMA and vice versa. One participant (4%) identified D-amphetamine as placebo. Thus, LSD was well distinguished from MDMA and D-amphetamine.

DISCUSSION
As hypothesized, LSD produced stronger and more distinct subjective effects compared with MDMA and D-amphetamine. Specifically, only LSD induced significant and marked alterations of consciousness on all 5D-ASC and MEQ subscales compared with placebo, and responses were also significantly greater compared with MDMA and D-amphetamine. MDMA was classified as D-amphetamine and vice versa (21%). One participant (4%) misidentified LSD as MDMA and vice versa. One participant (4%) misidentified D-amphetamine as placebo. Thus, LSD was well distinguished from MDMA and D-amphetamine.

96% and 100% of the participants on the day of administration and at the end of the study, respectively. However, similarities were also observed in the effects of all compounds on scales that measured positive drug effects. All of the drugs produced comparable ratings of “good drug effects” on the VAS, and ratings of “drug high,” “drug liking,” and “stimulated” on the VAS did not differ between LSD and MDMA. The present findings are overall consistent with previous reports on the effects of LSD [3, 4, 38, 50, 65], MDMA [18, 25, 28], and D-amphetamine [32]. In contrast to these previous studies, however, the present study compared the subjective responses to LSD, MDMA, and D-amphetamine using a within-subjects design. Subjective effects of various substances can differ, depending on the comparator that is used. For example, marked effects of MDMA on the 5D-ASC scale compared with inactive placebo have been previously reported [18]. However, when MDMA was compared with LSD in the present study, it induced only minimal and comparatively weak alterations of consciousness.

The present findings have clinical implications. First, acute effects of the LSD-like hallucinogen psilocybin on both the 5D-ASC scale and MEQ also used in the present study have been shown to predict long-term therapeutic outcomes in patients with anxiety and depression in previous studies [6–8]. Similarly, 5D-ASC scale and MEQ ratings correlated with changes in well-being and life satisfaction 1 year after LSD administration in healthy subjects in a previous study [10]. Thus, stronger acute responses to LSD on the 5D-ASC scale and MEQ, as documented in the present study in healthy participants and previously in patients [37], may also predict better therapeutic outcomes in studies that evaluate the
benefits of LSD-assisted psychotherapy in patients with anxiety and depression [66, 67]. However, this assumption needs to be verified in patients. Second, the present study found that MDMA produced some qualitatively similar (although less pronounced) positive effects compared with LSD, but with lower associated “bad drug effects” and anxiety. Thus, MDMA may produce less untoward effects than LSD, and this may favor its use in patients afraid to take LSD or at risk of adverse reaction (i.e., high neuroticism, high emotional lability, and young age [47]). In fact, MDMA is often used prior to LSD in substance-assisted psychotherapy in Switzerland so that patients can familiarize themselves with substance-induced states [66, 68, 69]. For example, MDMA could be used prior to LSD or psilocybin in substance-assisted psychotherapy so that patients can familiarize themselves with substance-induced states. In fact, MDMA has often been used in the first 1–3 sessions before the use of LSD in substance-assisted psychotherapy in Switzerland.

In the present study, we also directly compared the acute effects of MDMA and α-amphetamine and we hypothesized that MDMA would produce distinct subjective emotional effects compared with α-amphetamine. Previous studies have discussed the extent to which the effects of these amphetamines differ [25, 27, 28, 70]. The present study supports the view that the empathogen MDMA produces at least some clearly distinct effects
Distinct acute effects of LSD, MDMA, and \( \alpha \)-amphetamine

F Holze et al.

Fig. 4 Autonomic responses to LSD, MDMA, \( \alpha \)-amphetamine, and placebo. The data are expressed as mean ± SEM. All of the active substances produced significant sympathomimetic stimulation, reflected by increases in systolic and diastolic blood pressure, heart rate, body temperature, and pupil size. Importantly, the overall hemodynamic response, expressed as the rate–pressure product, was similarly increased by all of the active substances compared with placebo. However, \( \alpha \)-amphetamine produced significantly higher increases in blood pressure than LSD and MDMA. Conversely, LSD and MDMA produced greater increases in heart rate than \( \alpha \)-amphetamine during the first 4 h. The corresponding maximal effects and statistics are shown in Table 1.

In the present study, LSD, MDMA, and \( \alpha \)-amphetamine increased plasma oxytocin concentrations, which is thought to be attributable to the MDMA-induced release of 5-HT and 5-HT1A receptor stimulation [23]. Interestingly, the potent 5-HT1A and 5-HT2A receptor agonist LSD [5] did not significantly increase plasma oxytocin levels in the present study, in contrast to a higher dose of LSD and inactive placebo as the comparator in a previous study [3]. Supporting the view of distinct effects of MDMA and \( \alpha \)-amphetamine, 75% and 89% of the participants in the present study correctly identified MDMA and \( \alpha \)-amphetamine on the day of administration and at the end of the study, respectively. However, MDMA and \( \alpha \)-amphetamine also produced overlapping effects, including comparable increases in "open" and "talkative" on the VAS, "well-being" and "extraversion" on the AMRS, and a lack of significant "bad drug effects" or "anxiety" compared with placebo and in contrast to LSD. Similar partly overlapping effects of MDMA and lower doses of \( \alpha \)-amphetamine (10–20 mg) have been previously reported [33, 71]. Interestingly, both MDMA and \( \alpha \)-amphetamine seemed to produce relatively comparable "empathogenic" effects in the present study, whereas such effects were somewhat more unique to MDMA compared with the stimulant methylphenidate [27, 28]. Thus, MDMA and \( \alpha \)-amphetamine are more alike than MDMA and methylphenidate, but this remains to be clarified in future studies. Pharmacologically, \( \alpha \)-amphetamine and methylphenidate both activate the dopamine and norepinephrine systems without having relevant effects on 5-HT. However, \( \alpha \)-amphetamine also releases monoamines similarly to MDMA, in contrast to the pure uptake inhibitor methylphenidate [29, 72].

In the present study, LSD, MDMA, and \( \alpha \)-amphetamine produced comparable sympathomimetic activation, reflected by similar increases in the rate–pressure product, body temperature, and pupil size. Additionally, LSD, MDMA, and \( \alpha \)-amphetamine produced comparable amounts of total adverse effects as evidenced by similar scores on the List of Complaints (Table 1), although there were some differences between the substances regarding the specific complaints (Table S2). These findings indicate that the doses of the drugs were similar with regard to sympathomimetic effects, including cardiovascular system stimulation and somatic complaints. The finding that LSD produced relatively pronounced sympathomimetic effects confirmed our previous studies [3, 38] and contradicted the assumption that LSD does not increase blood pressure [67]. On the other hand, the study findings suggest that LSD is capable of inducing greater acute psychological effects (positive and negative) than MDMA and \( \alpha \)-amphetamine at doses that are producing comparable somatic adverse responses.

In the present study, we also determined plasma drug concentrations. Peak concentrations of MDMA and \( \alpha \)-amphetamine were similar to previous studies that tested identical doses [32, 39, 73]. The full pharmacokinetic data for LSD derived from the present study have been published elsewhere [50]. Importantly, slightly higher plasma concentrations of LSD were documented in the present study compared with a previous study that reportedly used the same dose (0.1 mg) [49]. The higher plasma concentrations in the present study can be explained by the use of a higher dose (0.096 mg) of LSD base (analytically confirmed content and stability) compared with a lower estimated dose of 0.070 mg in previous studies [38, 49], as discussed previously [50].

The main strength and novelty of the present study was that we employed a double-blind, placebo-controlled, within-subjects design that included different active substances and validated pharmacodynamic and substance concentration measurements. The present study also has limitations. We only used one dose
level of each substance. Full dose–response curves would need to be generated for each substance to achieve valid comparisons. However, we used a relatively low dose of LSD compared with the doses of MDMA and d-amphetamine and nevertheless found stronger effects of LSD compared with MDMA and d-amphetamine. Additionally, a previous study that used a higher dose of LSD (0.2 mg) showed significantly greater acute subjective effects of LSD compared with 0.1 mg LSD (the dose used in the present study), but autonomic stimulation was similar between doses [38]. Specifically, the higher dose produced both greater “good drug effect” and “bad drug effect” ratings on the VASs [38] and higher ratings of “blissful state,” “insightfulness,” and “changed meaning of percepts,” but no increase in “anxiety” on the SD-ASC [37] compared with the lower dose of LSD. Thus, both desired and untoward drug effects were dose-dependent and future multiple dose-level studies will be needed to further define ideal dose ranges. Thus, higher doses of LSD up to 0.2 mg that are already clinically used [2, 67] can be expected to produce even greater subjective effects than the dose (0.1 mg) that was used in the present study. The dose of MDMA that was used in the present study is in the upper range of doses that are used clinically; higher doses would not likely produce stronger positive subjective effects, but would likely result in more adverse somatic responses [39]. Finally, we found that the doses of all of the active substances were equivalent with regard to autonomic stimulation. Nevertheless, there is a need for additional studies including multiple dose levels and additional outcomes such as imaging.

In conclusion, the present study found that LSD induced different and more pronounced alterations of waking consciousness compared with MDMA and d-amphetamine in the same subjects. MDMA also showed partly distinct effects compared with d-amphetamine. The acute-effect profiles of LSD and MDMA will be useful to assist the dose selection for substance-assisted psychotherapy research and to inform patients and researchers on what to expect in terms of positive and negative acute responses to these substances.

FUNDING AND DISCLOSURE
The authors declare no competing financial interests. This work was supported by the Swiss National Science Foundation (grant no. 320030_170249).

ACKNOWLEDGEMENTS
We thank Patrick Dolder, Robert Widmer, and Samuel Harder for their help in conducting the study. We acknowledge the assistance of Michael Arends for proofreading the manuscript.

ADDITIONAL INFORMATION
Supplementary information is available for this paper at (https://doi.org/10.1038/s41386-019-0569-3).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Kebbs TS, Johansen PO. Over 30 million psychedelic users in the United States. F1000 Res. 2013;2:98.
2. Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42:2114–27.
3. Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.
4. Preller KH, Herdener M, Pokorny T, Planzer A, Kraehennann R, Stämpfli P, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451–7.
5. Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327–37.
6. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2017;8:974.
7. Grifths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.
8. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.
9. Grifths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22:621–32.
10. Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535–45.
11. Garcia-Romeu A, Grifths RR, Johnson MW. Psilocybin-assisted mystical experiences in the treatment of tobacco addiction. Curr Drug Abus Rev. 2015;7:157–64.
12. Mithoefer MC, Feducia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019; in press. https://doi.org/10.1007/s00213-019-05249-5.
13. Mithoefer MC, Mithoefer AT, Feducia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose–response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486–97.
14. Hysel CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645–52.
15. Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H. Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology. 2014;39:1564–63.
16. Hysel CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE. 2012;7:e36476.
17. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513–21.
18. Hysel CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmac Ther. 2011;90:246–55.
19. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("ecstasy") after pretreatment with the 5-HT2A antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23:396–404.
20. Dumont GJ, Sweep FC, van der Steen R, Hermens R, Donders AR, Touw DJ, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4:359–66.
21. Francis SM, Kirkpatrick MG, de Wit H, Jacob S. Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration. Psychoneuroendocrinology. 2016;74:92–100.
22. Ramos L, Hicks C, Kevin R, Caminer A, Narlawar R, Kassiou M, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. J Psychopathol. 2014;2:404–13.
23. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4-methylenedioxymethamphetamine ("ecstasy"). Neuroscience. 2007;146:509–14.
24. Nichols DE. Differences between the mechanism of action of MDMA, MBD8, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs. 1991;23:229–49.
25. Bershad AK, Miller MA, Baggott MJ, de Wit H. The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants? J Psychopharmacol. 2016;30:1248–58.
26. Hysel CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al. Pharmacokinetic and pharmacodynamic effects of methylenediate and MDMA.
administered alone and in combination. Int J Neuropsychopharmacol. 2014;17:371–81.
27. Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014;28:847–56.
28. Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology. 2018;235:467–79.
29. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharm. 2013;168:458–70.
30. Vezzoli CD, Miller GM, Madras BK. MDMA (ecstasy) and human dopamine, nor-epinephrine, and serotonin transporters: implications for MDMA-induced neu-rotoxicity and treatment. Psychopharmacology. 2007;189:489–503.
31. Dolder PC, Strajhar P, Vizeli P, Odermatt A, Liechti ME. Acute effects of lisdex-amfetamine and α-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects. Psychopharmacology. 2018;235:1389–402.
32. Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharm. 2017;8:617.
33. Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with α-amphetamine and mCPP. Drug Alcohol Depend. 2003;72:33–44.
34. Newhouse PA, Belensky G, Thomas M, Thorne D, Sing HC, Fertig J. The effects of α-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacology. 1989;2:153–64.
35. Rush CR, Essman WD, Simpson CA, Baker RW. Reinforcing and subject-rated effects of methylphenidate and α-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol. 2001;21:273–86.
36. Hintzen A, Passie T. The pharmacology of LSD: a critical review. Oxford: Oxford University Press; 2010.
37. Liechti ME, Dolder PC, Schmid Y. Alterations in consciousness and mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–83. discussion 84–92.
38. Dolder PC, Schmid Y, Mueller F, Borgwardt S, Liechti ME. LSD acutely impairs fear discrimination in healthy male volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies. J Psychopharmacol. 2017;31:589–98.
39. Janke W, Debus G. Die Eigenschaftswörterliste. Göttingen: Hogrefe; 1978.
40. Dittrich A. The standardized psychometric assessment of altered states of con-sciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31(Suppl 2):80–4.
41. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010;5:e12412.
42. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–83. discussion 84–92.
43. Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29:1182–90.
44. Martin WR, Sloan JW, Saripa JD, Jaisinski DR. Physiologic, subjective, and beha-vioral effects of amphetamine, methamphetamine, ephedrine, phentermine, and methylphenidate in man. Clin Pharm Ther. 1971;12:245–58.
45. Bopp G, Bender W, Schütz CG. Validierung der Deutschen Version des Addiction Research Center Inventory (ARCI). Suchtmédizin. 2005;7:152–8.
46. Hysek CM, Vollenweider FX, Liechti ME. Effects of a β-blocker on the cardiovas-cular response to MDMA (ecstasy). Emerg Med J. 2010;27:586–9.
47. Hysek CM, Liechti ME. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvediol, and doxazosin on pupillary light reflex. Psychopharmacology. 2012;224:363–76.
48. Zerssen DV. Die Beschwerden-Liste. Münchener Informationssystem. München: Psychis; 1976.
49. Holt-Lunstad J, Birmingham WA, Light KC. Influence of a “warm touch” support intervention among married couples on ambulatory blood pres-sure, oxytocin, alpha amylase, and cortisol. Psychosom Med. 2008;70:767–85.
50. Akimoto H, Oshima S, Sugiyama T, Negishi A, Nemoto T, Kobayashi D. Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression. Behav Brain Res. 2019;359:342–52.
51. Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:379–90.
52. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained sub-jective effects. J Psychopharmacol. 2015;29:57–68.
53. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513–20.
54. Gasser P. Die psycholytische Therapie in der Schweiz von 1988-1993. Schweiz Arch Neurol Psychiatr. 1996;147:59–65.
55. Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psycho-pharmacol. 2013;27:40–52.
56. Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68:1134–40.
57. Johanson CE, Kidley M, Gatchalian K, Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to dis-criminate among d-amphetamine, meto-chlorophenylpiperazin and placebo. Drug Alcohol Depend. 2006;81:27–36.
58. Simmler LD, Rickli A, Schramm Y, Hoefer MC, Liechti ME. Pharmacological profiles of aminodindanes, pipерazines, and pipradrol derivatives. Biochem Pharmacol. 2008;76:23–37.
59. Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylenedioxyamphetamine in a controlled study in healthy subjects. Pharmacogenet Genom. 2016;26:397–401.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019

Neuropsychopharmacology (2019) 0:1 – 10

SPRINGER NATURE

10 F Holze et al.